May. 18 at 3:49 PM
$ABEO "Abeona Therapeutics’ latest earnings call struck an overall optimistic tone, with strong early commercial traction for ZEVASKYN offsetting heavier spending and cash burn. Management highlighted accelerating revenue, expanding treatment capacity and robust payer coverage, while acknowledging operational bottlenecks and higher costs tied to the launch and a new oncology program.
Early Revenue Surge From ZEVASKYN
Net product revenue climbed to
$8.7 million in Q1 2026, driven by three commercially insured ZEVASKYN patients and marking a roughly 262% jump from
$2.4 million in Q4 2025. This sharp quarter‑over‑quarter acceleration, though from a small base, signals that early demand is converting into meaningful top‑line growth.
https://www.theglobeandmail.com/investing/markets/stocks/ABEO/pressreleases/1946522/abeona-therapeutics-signals-strong-early-zevaskyn-launch/
